EyePoint Inc (EYPT)

• Market cap: $365M
• 1 day: -0.47%
• 5 days: -6.62%
• 1 month: -67.59%
• 3 months: -66.16%
• 6 months: -71.65%
• Year to date: -75.8%
• 1 year: -68.27%
• 5 years: -57.74%
• 10 years: -88.96%
• Sector: Healthcare
• Industry: Biotechnology

About: EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Employees: 214